Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teneobio
Biotech
Amgen stops cancer trial, taking $650M BiTE out of earnings
Amgen took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in the $900 million acquisition of Teneobio two years ago.
Nick Paul Taylor
Oct 31, 2023 8:59am
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets
Aug 5, 2022 7:50am
TeneoTwo, put in play by Amgen, lands $100M AstraZeneca buyout
Jul 5, 2022 7:00am
Teneobio snapped up by Amgen for $2.5B
Jul 28, 2021 4:35am
AbbVie vies for the multiple myeloma skies with TeneoOne buy
Jun 24, 2021 11:40am
Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma
Apr 2, 2020 8:30am
